This report contains market size and forecasts of Artificial Blood Substitute in China, including the following market information:
China Artificial Blood Substitute Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Artificial Blood Substitute companies in 2020 (%)
The global Artificial Blood Substitute market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of 22.4% during 2021-2027.
The China Artificial Blood Substitute market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Artificial Blood Substitute Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Artificial Blood Substitute Market,

By Type

, 2016-2021, 2022-2027 ($ Millions)
China Artificial Blood Substitute Market Segment Percentages,

By Type

, 2020 (%)
Perfluorocarbon-based Oxygen Carrier (PFBOC)
Hemoglobin-based Oxygen Carrier (HBOC)

China Artificial Blood Substitute Market,

By Application

, 2016-2021, 2022-2027 ($ Millions)
China Artificial Blood Substitute Market Segment Percentages,

By Application

, 2020 (%)
Military
Civil

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Artificial Blood Substitute revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Artificial Blood Substitute revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Aurum Biosciences Ltd.
HEMARINA SA
HbO2 Therapeutics
KaloCyte Inc.
SpheriTech Ltd.
NuvOx Pharma